|1.||Gyertyán, István: 2 articles (10/2007 - 05/2005)|
|2.||Lu, Dah-Yuu: 1 article (01/2013)|
|3.||Chen, Yi-Hung: 1 article (01/2013)|
|4.||Chuang, Chieh-Min: 1 article (01/2013)|
|5.||Ivanic, Boris: 1 article (01/2013)|
|6.||Lin, Jaung-Geng: 1 article (01/2013)|
|7.||Zapata, A: 1 article (09/2008)|
|8.||Gasior, M: 1 article (09/2008)|
|9.||Witkin, J M: 1 article (09/2008)|
|10.||Kaminski, R: 1 article (09/2008)|
|1.||Schizophrenia (Dementia Praecox)
05/29/2007 - "The capacity of SB-277011-A to trigger immediate early gene expression in these limbic regions of rat brain adds to a growing consensus of the potential utility of dopamine D(3) receptor antagonism in psychiatric disorders including schizophrenia and drug dependency."
07/01/2001 - "It is presumed that GlaxoSmithKline has taken over from SmithKline Beecham in investigating the highly selective dopamine D3 antagonist SB-277011 and its analogs for the potential treatment of schizophrenia  following the merger of Glaxo Wellcome and SmithKline Beecham in December 2000 . "
09/01/2000 - "The effect of SB-277011-A on isolation-induced prepulse inhibition deficit suggests that blockade of dopamine D(3) receptors may benefit the treatment of schizophrenia."
09/01/2008 - "The D(3) antagonist SB-277011-A [4-quinolinecarboxamide,N-[trans-4-[2-(6-cyano-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]-cyclohexyl]-(9CI)] prevented the anticonvulsant effect of the D(3)/D(2) receptor agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-benzopyrano[4,3-b]-1,4-oxazin-9-ol)] on cocaine-induced seizures. "
01/01/2013 - "While the dopamine D3 receptor antagonist, SB-277011-A (30 mg/kg; s.c), did not by itself affect cocaine-induced seizure severity, it prevented the effects of EA on cocaine-induced seizures. "
07/01/2001 - "In November 2000, data presented at the 30th Neuroscience meeting in New Orleans, LA, demonstrated that D3 receptor blockade with SB-277011 specifically altered neurochemical effects in the nucleus accumbens without the non-selective effects, such as catalepsy, seen with some other antagonists ."
10/31/2007 - "Further to that, we report that SB 277011 exerted a dose-dependent dampening on the development of haloperidol-induced catalepsy in the dose-range of 13.5-30 mg/kg p.o. "
10/31/2007 - "The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats."
|4.||Amnesia (Dissociative Amnesia)
|2.||Dopamine D3 Receptors
|3.||Cocaine (Cocaine HCl)
|6.||1- (2- methoxy- phenyl)- 4- (4- (4- (6- imidazol(2,1- b) thiazolyl)- phenoxy)- butyl- 4- (14)C)- piperazine dimethane